Myasthenia gravis after botulinum toxin A for Meige syndrome.

@article{Tarsy2000MyastheniaGA,
  title={Myasthenia gravis after botulinum toxin A for Meige syndrome.},
  author={Daniel Tarsy and N Bhattacharyya and G Borodic},
  journal={Movement disorders : official journal of the Movement Disorder Society},
  year={2000},
  volume={15 4},
  pages={
          736-8
        }
}
Botulinum toxin A (BTX-A) produces muscle weakness by blocking presynaptic release of acetylcholine at the neuromuscular junction. Following treatment with usual clinical doses, weakness is limited to local or adjacent muscles without clinically important effects on muscles in other body regions. However, abnormal neuromuscular transmission and remote type II muscle atrophy 6 without clinical weakness have been identified in muscles remote from the site of BTX-A injection. Recently, several… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Torsional nystagmus induced by subthalamic nucleus stimulation.

  • Movement disorders : official journal of the Movement Disorder Society
  • 2008

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis.

  • Movement disorders : official journal of the Movement Disorder Society
  • 1994